Autologous stem cell therapy for inherited and acquired retinal disease

Regen Med. 2018 Jan;13(1):89-96. doi: 10.2217/rme-2017-0089. Epub 2018 Jan 23.

Abstract

The mammalian retina, derived from neural ectoderm, has little regenerative potential. For conditions where irreversible retinal pigment epithelium or photoreceptor cell loss occurs, advanced techniques are required to restore vision. Inherited retinal dystrophies and some acquired conditions, such as age-related macular degeneration, have a similar end result of photoreceptor cell death leading to debilitating vision loss. These diseases stand to benefit from future regenerative medicine as dietary recommendations and current pharmacologic therapy only seek to prevent further disease progression. Cell-based strategies, such as autologously derived induced pluripotent stem cells, have come a long way in overcoming previous technical and ethical concerns. Clinical trials for such techniques are already underway. These trials and the preceding preclinical studies will be discussed in the context of retinal disease.

Keywords: autologous; induced pluripotent stem cells; retinal degeneration; stem cell.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autografts
  • Genetic Diseases, Inborn / pathology
  • Genetic Diseases, Inborn / therapy*
  • Humans
  • Induced Pluripotent Stem Cells / metabolism
  • Induced Pluripotent Stem Cells / pathology
  • Induced Pluripotent Stem Cells / transplantation*
  • Regenerative Medicine / methods*
  • Regenerative Medicine / trends*
  • Retinal Dystrophies / pathology
  • Retinal Dystrophies / therapy*
  • Stem Cell Transplantation / methods*